European Passive Transdermal Drug Delivery Market Research Report
- Report Code: PA 1002
- Publish Date: Upcoming
The European passive transdermal drug delivery market, mainly driven by ‘patent cliffs’, increased incidence of chronic diseases, increasing competition, improving patient compliance, reformulation and repositioning of drugs using advanced oral delivery systems, and huge investments made by big pharmaceutical companies, was valued at $3.27 billion in 2013 and is expected to reach $5.19 billion by 2018, at a CAGR of 9.6% from 2013 to 2018.
Europe holds the second position, in terms of value, of the overall pharmaceutical market. The European pharmaceutical market was worth $228 billion in 2011, accounting for 26.8% of the global pharmaceuticals market. The industry invested $36.1 billion in R&D in 2011, provided direct employment to 660,000 Europeans, and generated three to four times more employment indirectly. However, the pharmaceutical markets in the major five European countries, namely Germany, France, the U.K., Italy, and Spain, grew at an average rate of 2.6% in 2011, due to the overall slow economic conditions in the region and the increasing competition from emerging nations.
The report also provides an extensive competitive landscaping of the leading companies operating in the market. The main companies in the market include Novartis, Johnson & Johnson, 3M Company, and Noven, among others. Furthermore, segment and country-specific company shares, news & deals, M&A, segment-specific pipeline products, product approvals, and product recalls of the major companies have been detailed in this report.
Customization Options:
Along with the market data, customize the MMM assessments to meet your company’s specific needs. Customize to get a comprehensive summary of the industry standards and deep dive analysis of the following parameters:
Product Analysis
- Usage pattern (in-depth trend analysis) of products (segment-wise)
- Product matrix, which gives a detailed comparison of product portfolio of each company, mapped at country and sub-segment levels
- End-user adoption rate analysis of the products (segment-wise and country-wise)
- A comprehensive coverage of product approvals, pipeline products, and product recalls
Pharmacists Forum
- Fast turn-around analysis of pharmacists’ responses to market events and trends
- Pharmacists’ opinions about passive transdermal drug delivery products from different companies
- Pharmacists’ qualitative inputs on epidemiology data
- Pattern analysis of usage of drugs by physicians
Brand/Product Perception Matrix
- A comprehensive study of customers’ perception and behavior through our inbuilt social connect tool checking the virality and tonality of blogs
- An analysis of overall brand usage and familiarity and brand advocacy distribution (detractor/neutral/familiar)
Please fill in the form below to receive a free copy of the Summary of this Report
Please visit http://www.micromarketmonitor.com/custom-research-services.html to specify your custom Research Requirement
| PRODUCT TITLE | PUBLISHED | |
|---|---|---|
|
|
North American Transdermal Drug Delivery Systems Market The North American Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs using advanced oral delivery systems, huge investment made by big pharmaceutical companies.The Market was Valued at $7.6 billion in 2013 and expected to be $12.7 billion by 2018, growing at a CAGR of 10.9%. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
European Transdermal Drug Delivery Systems Market The European Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs using advanced oral delivery systems, huge investment made by big pharmaceutical companies.The Market was Valued at $3.6 billion in 2013 and expected to be $5.8 billion by 2018, growing at a CAGR of 9.9 %. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
|
|
Asian Transdermal Drug Delivery Systems Market The Asian Transdermal Drug Delivery Market is mainly driven by patent cliffs and increased incidence of chronic diseases, increasing competition and improving patient compliance, and reformulation and repositioning of drugs using advanced oral delivery systems, huge investment made by big pharmaceutical companies.The Market was Valued at $1.5 billion in 2013 and expected to be $3.0 billion by 2018, growing at a CAGR of 14.8 %. The Transdermal Drug Delivery Market analyzes the market by segments such as Active Transdermal Drug Delivery, and Passive Transdermal Drug Delivery. The prominent players in this Market are Novartis, Johnson & Johnson, 3M Company, Noven. |
Upcoming |
